Kodiak Sciences Inc (KOD) Dividend History

Company News

• Diabetic Retinopathy Global Clinical Trials Review 2024: Region, country (G7 & E7), phase, trial status, End-points Status and Sponsor Type

  The report provides an overview of the global clinical trials landscape for diabetic retinopathy, including details on trial numbers, enrollment, and status across different regions, countries, phases, and sponsor types. It also highlights prominent drugs and companies involved in these trials.

  GlobeNewswire Inc.

  Featured Companies: ABBV ALC PFE REGN
• Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?

  Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.

  Zacks Investment Research

  Featured Companies: ALXO ANVS CGEN
• Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?

  Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  Zacks Investment Research

  Featured Companies: HALO
• Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus

  Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.

  Zacks Investment Research

  Featured Companies: ANIP ANVS LGND
• Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks

  Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.

  Zacks Investment Research

  Featured Companies: ADMA REGN